WILSON JAMES N sold $1.1M of CORT (indirect holdings)

WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $111.43 ($110.49–$112.64, $1.11M total) across 3 trades on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WILSON JAMES N
Published Aug 18, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosed fact is the size, timing, and pricing range of the director’s open-market sale under a 10b5-1 plan; it does not include new corporate developments.

02

Market read

Traders may note insider selling activity, but the 10b5-1 structure and lack of new fundamentals suggest limited trading edge.

03

What to watch

The article does not disclose any change in company guidance, trial results, or financing needs; without those, the sale’s informational content is limited.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18, trades executed 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported from an indirect holding by a director.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics Form 4 shows director Wilson James N sold 10,000 shares in open-market trades at about $110.49 to $112.64 on 2026-08-14.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a routine 10b5-1 sale by a director, with no accompanying company-specific operational or financial catalyst disclosed in the text.

Market effects

No sector read-through is provided; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect planned liquidity rather than bearish expectations, so traders may overreact if they treat it as a signal.

Key entities

  • CORCEPT THERAPEUTICS INC

    Company whose Form 4 insider sale is disclosed.

  • WILSON JAMES N

    Director reporting an indirect open-market sale of 10,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.